Why Take Folic Acid During Chemotherapy?

Folic acid is given during certain chemotherapy regimens to protect healthy cells from the toxic side effects of drugs that work by disrupting folate metabolism. The most prominent example is pemetrexed, a drug used mainly in lung cancer, where adding folic acid and vitamin B12 dropped the rate of severe neutropenia from roughly a third of patients to just a few percent. But the story is not as simple as “folic acid makes chemo safer.” Depending on which drug you are receiving, folic acid can serve completely different purposes, and in some situations it can actually increase the risk of side effects.

How Antifolate Chemotherapy Drugs Work

Your body needs folate to build DNA. Two enzymes in particular, thymidylate synthase and dihydrofolate reductase, rely on folate to produce the building blocks cells need to copy their genetic material and divide.¹ These enzymes are active in every dividing cell, but they are especially busy in cancer cells, which divide relentlessly. Antifolate chemotherapy drugs exploit this vulnerability by blocking those enzymes, starving rapidly dividing cells of the raw materials they need to replicate.

Methotrexate, one of the oldest chemotherapy agents still in wide use, binds tightly to dihydrofolate reductase and locks it up so it cannot process folate.² Pemetrexed goes further: it hits multiple folate-dependent enzymes at once, including thymidylate synthase, dihydrofolate reductase, and enzymes involved in building purines, the other critical ingredient for DNA.³ The problem is that these drugs do not exclusively target cancer cells. Normal tissues that turn over quickly, such as the lining of your gut, your bone marrow, and the inside of your mouth, also depend heavily on folate-driven DNA synthesis. When those tissues get caught in the crossfire, you get the side effects people dread: mouth sores, dangerously low white blood cell counts, and gut inflammation.

Folic Acid Supplementation With Pemetrexed

Pemetrexed is the clearest case where folic acid is prescribed alongside chemotherapy as standard practice. Early clinical experience with pemetrexed showed alarming rates of severe toxicity, but researchers discovered that supplementing patients with folic acid and vitamin B12 transformed the drug’s safety profile. Premedication with folic acid for five to seven days before beginning treatment, continued throughout the chemotherapy cycles and for three weeks after stopping pemetrexed, resulted in a dramatic reduction in toxicity: grade 4 neutropenia fell from 32% to 3%, severe mucositis dropped from 5% to about 1%, and treatment-related deaths fell from 5% to essentially zero.⁴

A natural concern is whether giving patients folic acid might also shield the cancer from pemetrexed, undermining the whole point of treatment. Laboratory studies have addressed this directly, and the results are reassuring. In experiments on multiple lung cancer cell lines, adding folic acid and vitamin B12 alongside pemetrexed did not reduce the drug’s ability to kill cancer cells. In fact, the combination actually enhanced sensitivity: in one cell line, only about 34% of cancer cells survived the combined treatment compared with a higher survival rate under pemetrexed alone.⁵ The likely explanation is that adequate folate allows pemetrexed to be processed into its more potent polyglutamated forms inside cancer cells, improving uptake and retention of the drug where it matters most.

A randomized trial in patients with non-squamous non-small cell lung cancer confirmed that folic acid and B12 supplementation reduces blood-related toxicity during pemetrexed-based chemotherapy in the clinical setting, not just the laboratory.⁶ This is why folic acid supplementation is now a mandatory part of pemetrexed treatment protocols worldwide.

Leucovorin Rescue After High-Dose Methotrexate

Folic acid supplementation with pemetrexed is a daily pill you take throughout treatment. Leucovorin rescue after methotrexate is something different: a time-sensitive intervention that can be the difference between manageable side effects and a medical emergency.

High-dose methotrexate, used in cancers like osteosarcoma and certain leukemias, is given at doses that would be lethal to normal tissues if left unchecked. The strategy is to flood the body with methotrexate long enough to damage cancer cells, then administer leucovorin (also called folinic acid) to “rescue” healthy tissues. Leucovorin is a reduced form of folate that can bypass the enzyme methotrexate blocks, allowing normal cells to resume DNA synthesis. The original idea behind leucovorin rescue was that providing reduced folate to normal cells would reverse the metabolic block while cancer cells, which may be less able to take up the rescue agent, remain damaged.⁷

Timing is critical. Research has found that starting leucovorin rescue within 36 hours of methotrexate infusion is safe, but delaying until 42 to 48 hours leads to significant toxicity, particularly at higher methotrexate doses.⁸ This is not a situation where you can casually miss a dose. Oncology teams monitor methotrexate blood levels closely and adjust leucovorin doses accordingly, sometimes continuing rescue for days if the drug is clearing slowly.

Leucovorin With 5-Fluorouracil Serves a Different Purpose Entirely

If you are receiving 5-fluorouracil (5-FU), a drug commonly used in colorectal cancer, your oncologist may also prescribe leucovorin. But here the logic is flipped. Leucovorin is not given to protect you from 5-FU; it is given to make 5-FU hit cancer cells harder.

5-FU works partly by disguising itself as a folate-related molecule and tricking thymidylate synthase into binding with it. When leucovorin is present, it provides the reduced folate cofactor that helps lock 5-FU’s active metabolite onto thymidylate synthase in a tight, stable complex, inactivating the enzyme far more effectively than 5-FU alone.⁹ In other words, leucovorin is a biomodulator: it boosts the drug’s anticancer activity rather than reducing its side effects. This means 5-FU plus leucovorin can actually cause more side effects than 5-FU alone, because the drug is working more potently against all rapidly dividing cells, both cancerous and normal.

This distinction matters a lot for patients. If someone on 5-FU/leucovorin hears that folic acid is used during chemotherapy to reduce side effects, they might assume their leucovorin is doing the same thing. It is not. Understanding the reason behind each drug in your regimen helps you have better conversations with your care team.

When Folic Acid Supplementation Can Be Harmful

Not all chemotherapy patients benefit from folic acid, and some may be harmed by it. A cohort study of colorectal cancer patients found that those who took folic acid supplements during treatment had a higher risk of chemotherapy-induced toxicity, with roughly double the hazard compared to those who did not supplement. Even having detectable unmetabolized folic acid in the blood during treatment was associated with increased toxicity risk.¹⁰

This finding makes biological sense when you consider the 5-FU/leucovorin mechanism described above. If you are already receiving leucovorin to enhance 5-FU’s potency, adding extra folic acid on top of that could further amplify the drug’s effects on normal tissues without providing any additional anticancer benefit. The result is more damage to the gut lining, bone marrow, and other sensitive tissues.

A systematic review of folate, folic acid, and chemotherapy-related toxicity noted that the evidence base is still limited, with most studies involving small numbers of patients. Among studies looking at antifolate drugs like methotrexate and pemetrexed, supplementation generally appeared to reduce toxicity. But the picture was more complicated for non-antifolate regimens.¹¹ The takeaway is clear: do not start folic acid supplements on your own during cancer treatment. What helps with one drug may hurt with another. Supplementation decisions belong to your oncologist, who knows which drugs you are on and how they interact with folate metabolism.

Folic Acid Versus Folinic Acid

Patients sometimes encounter both terms and wonder whether they are the same thing. They are related but not identical. Folic acid is the synthetic form of folate found in supplements and fortified foods. Your body has to convert it through several steps before it becomes the active folate compounds your cells actually use. Folinic acid (leucovorin) is already partially converted, so it enters folate metabolism further downstream and acts faster.

Pharmacokinetic studies have shown that the final metabolites produced from folic acid and leucovorin are the same: 5-methyltetrahydrofolate, tetrahydrofolate, and the other active folate forms. The difference is speed. Folic acid metabolites build up more slowly and persist longer in the body, while leucovorin metabolites appear and clear faster.¹² This is why leucovorin is the form used for time-sensitive rescue after high-dose methotrexate, where you need folate to reach cells quickly. Folic acid, with its slower but longer-lasting profile, is a better fit for the sustained daily supplementation used during pemetrexed treatment.

A recent randomized trial even explored using folinic acid as prophylaxis during pemetrexed treatment, administering it on days two through four after each chemotherapy cycle. Patients who received folinic acid had higher white blood cell counts after their first cycle, suggesting it may offer an additional layer of protection on top of daily folic acid for patients who are especially vulnerable to bone marrow suppression.¹³

How Genetics Affect Your Response

Not everyone processes folate the same way, and genetic variation helps explain why two patients on the same chemotherapy regimen can have wildly different side-effect profiles. A key player is the gene MTHFR, which codes for an enzyme that converts one form of folate into another. Common variants of this gene reduce the enzyme’s efficiency, meaning folate gets processed more slowly.

In a study of ovarian cancer patients receiving chronic low-dose methotrexate, those carrying two copies of the less efficient MTHFR variant (the TT genotype at position 677) had a dramatically higher rate of severe toxicity: about 77% experienced grade 3 or 4 side effects, compared with fewer than 10% of patients with other genotypes.¹⁴ The TT patients also had substantially higher levels of homocysteine after treatment, a marker that their folate metabolism was struggling to keep up.

The clinical implications of MTHFR genotyping remain debated. A meta-analysis focusing specifically on patients with blood cancers found no significant overall association between MTHFR variants and methotrexate toxicity, though there was a trend toward increased liver toxicity in acute lymphoblastic leukemia patients carrying the mutation.¹⁵ The mixed findings likely reflect the fact that cancer type, drug dosing, and the rest of a person’s genetic makeup all influence outcomes. Still, the evidence is enough to suggest that MTHFR variants may eventually become part of routine pre-treatment screening, helping oncologists identify patients who need closer monitoring or adjusted folate supplementation.¹⁶

Practical Timing and What Patients Should Know

If you are prescribed folic acid with pemetrexed, the standard protocol calls for starting it at least five to seven days before your first infusion. You continue taking it daily throughout treatment and for 21 days after your last dose. A vitamin B12 injection is typically given at the same time, usually every nine weeks. These are not optional extras; they are built into the treatment protocol because pemetrexed’s safety profile depends on them.

That said, a case series looking at patients who did not receive a full week of folic acid before starting pemetrexed found that most tolerated treatment without major pemetrexed-related toxicity.⁴ This does not mean you should skip the lead-in period if you can avoid it, but it offers some reassurance that a day or two of delay does not necessarily mean disaster. In clinical practice, oncologists sometimes face the dilemma of starting urgent treatment before the full supplementation window has passed, and findings like these inform those judgment calls.

For leucovorin rescue after methotrexate, the timing windows are stricter and monitored by your treatment team through blood draws. Patients do not typically manage this themselves; the leucovorin is given intravenously or as precisely scheduled oral doses in a hospital or clinic setting.

Folate Receptors as Drug Targets

Beyond its role as a supplement during treatment, folate has become interesting to cancer researchers for another reason. Many tumors overexpress a protein called folate receptor alpha on their surfaces, essentially putting out extra “hands” to grab folate from the bloodstream. This receptor is found at high levels in ovarian, breast, and lung cancers, while its presence on normal tissues is much more limited.¹⁷

This difference has spurred the development of drugs and drug-delivery systems designed to exploit folate receptor alpha. The idea is to attach a toxic payload to a folate molecule or a folate-mimicking antibody, creating a Trojan horse that gets preferentially sucked into cancer cells while leaving normal tissues relatively unharmed. Several of these approaches are in clinical trials, and the receptor’s association with tumor aggressiveness and patient outcomes has further fueled interest. Whether any of these strategies ultimately change standard care remains to be seen, but the concept illustrates how deeply folate biology is intertwined with cancer at every level, from basic cell division to the design of next-generation therapies.